Plain English Summary
Background and study aims
Coronary artery disease (CAD), also known as ischemic heart disease, is one of the leading causes of death worldwide. CAD develops because of the build-up of fatty deposits (plaque) on the walls of the coronary arteries (the arteries that supply the heart with oxygen-rich blood). CAD includes a number of diseases, such as angina (pain or pressure in the chest), which is worsened by physical activity or stress. The current treatments for CAD focus on relieving the symptoms and reducing the risk of a heart attack (myocardial infarction). New treatments are emerging, using adult stem cells from patients’ own bodies to re-build heart tissue (neocardiogenesis). The aim of this study is to find out whether the use of low frequency vibration massage will help stimulate the growth of new heart tissue in patients with CAD.
Who can participate?
Adults suffering from either angina or ischemic heart disease, who have been deemed unsuitable for heart surgery.
What does the study involve?
Participants are divided into two groups, based on the condition they are suffering from. These groups are then randomly allocated into two further groups who receive different treatments daily. Those in the first group receive half hour sessions of high setting (penetrative) vibration to their upper back via the Vibro-Acoustic Therapy system. Those in the second group receive low setting (non-penetrative) sham therapy to their lower back. The extent of their heart disease and how well their hearts are functioning is measured before the therapy, immediately after, and again three and six months after the therapy.
What are the possible benefits and risks of participating?
Participants may benefit from an improvement of the symptoms of their disorders. There are no long term risks to participants of the study, however continuously applied LFV may be a mild stressor to the heart in some cases angina and /or a sensation of shortness of breath may be temporarily brought on by the treatment.
Where is the study run from?
False Creek Surgical Centre (Canada)
When is the study starting and how long is it expected to run for?
August 2015 to August 2017
Who is funding the study?
Ahof Biophysical Systems Inc. (Canada)
Who is the main contact?
Mr Andrew Hoffman
andrew.hoffmann11@gmail.com
Trial website
Contact information
Type
Scientific
Primary contact
Mr Andrew Hoffmann
ORCID ID
Contact details
Ahof Biophysical Systems Inc.
3858 Regent Street
Burnaby
British Columbia
V5C4G8
Canada
+1 604 779 3571
andrew.hoffmann11@gmail.com
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
Coronary Revascularization by ExtrAcorporeal Transthoracic Epi-myocardial VIBration
Acronym
CREATE-VIB trial
Study hypothesis
Penetrative upper back 35 Hz sinusoidal Low Frequency Vibration massage applied daily for 30 minute sessions over a 3 month period via the VTS – 1000 Vibro-Acoustic Therapy system will stimulate neo-coronary growth, enhance myocardial perfusion, and improve clinical outcomes in Refractory Angina and/or Ischemic Heart Failure patients.
Ethics approval
Not provided at time of registration.
Study design
A single center prospective blinded interventional randomized controlled pilot study.
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Condition
Refractory Angina (CCS anginal class 3 or 4), and/or Ischemic Heart Failure (NYHA functional class 2, 3 or 4).
Intervention
Thirty ischemic heart test subjects will be divided into two parallel groups matched for condition and class, where-after the groups will be randomized to receive half hour sessions of penetrative (high setting) 35 Hz vibration via the VTS – 1000 Vibro-Acoustic Therapy system to their upper back vs. non-penetrative (low setting) sham therapy. Interventions planned daily (with a minimum compliance rate of 75%) - over a 3 month period.
Intervention type
Device
Phase
Drug names
Primary outcome measures
1. Stress SPECT MPI (maximal exercise) to assess myocardial perfusion by global perfusion at rest (SSS – Summed Stress Score) and stress (SRS – Summed Rest Score), pre vs. post therapy. Time to 1 mm and 2 mm ST depression, time to and degree of anginal symptoms, and functional capacity (total time on treadmill) should be additionally noted on a case by case basis.
2. Stress Echo (maximal exercise) to assess evaluation of inducible RWMAs by hypo-akinetic segment count and Wall Motion Score Index (WMSI) - pre vs. post therapy.
3. Walking test (20 to 100 meter; patient encouraged to walk as long and as brisk as possible) to assess NHYA heart failure classification and CCS anginal class- pre vs. immediate post, 3 months and 6 months post therapy.
Secondary outcome measures
1) Anginal count by month long diary record (average frequency of anginal episodes per day), pre vs. immediate post, three and six months post therapy.
2) Nitroglycerine (NTG) use count by month long diary record (average frequency of NTG usage per day), pre vs. immediate post, three and six months post therapy.
Overall trial start date
26/08/2015
Overall trial end date
12/08/2017
Reason abandoned
Eligibility
Participant inclusion criteria
1. Adults (> 35 years of age)
2. Patient weight up to 120 kg
3. Stable, CCS class 3 or 4 angina pectoris, and/or NYHA functional class 2, 3 or 4 ischemic heart failure
4. A positive Exercise Treadmill Test (ETT), and at least one of a Nuclear SPECT MPI perfusion study showing evidence for reversible myocardial ischemia, and/or a Stress Echo showing at least one provoked Regional Wall Motion Abnormality (RWMA)
5. An interpretable QRS complex enabling ST analysis during stress testing (i.e. no left bundle branch block–LBBB, or paced beats during stress)
6. Ability to present for daily hospital appointments (with a minimal expected compliance of at least 75%), over a three month period
7. Patient was declined to Coronary Artery Bypass Graft (CABG) surgery and / or Percutaneous Coronary Intervention (PCI) by the attending cardiologist or surgeon, and has no plans to undertake other forms of coronary angiogenic therapy (e.g. EECP, ESMR etc.) during the study period
8. Patient has received optimized medical therapy
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
30 (15 control, 15 receiving therapy)
Participant exclusion criteria
1. Left bundle branch block (LBBB)
2. Paced Rhythm
3. Severe Aortic Stenosis (valve area up to 1.0 cm2)
4. Patient’s weight greater than 120 kg
5. Cannot walk on treadmill
Recruitment start date
02/01/2016
Recruitment end date
02/01/2017
Locations
Countries of recruitment
Canada, United States of America
Trial participating centre
False Creek Surgical Centre
555 West 8th Avenue
Vancouver, British Columbia
V5Z 1C6
Canada
Funders
Funder type
Industry
Funder name
Ahof Biophysical Systems Inc.
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Once the study is completed data will be synthesized and written up in view to publication in a peer reviewed journal.
Intention to publish date
01/06/2017
Participant level data
To be made available at a later date
Results - basic reporting
Publication summary